Oslo, Oct 4, 2013: Norwegian molecular diagnostics company Genetic Analysis today announced that it has secured $2million to fund the CE-marking and launch of its DNA-based GA-map™ test for dysbiosis in IBS patients. The funding follows the appointment of industry veteran Kari Stenersen as CEO. Formerly marketing director at Axis-Shield, Stenersen was responsible for the highly successful Afinion POC system,
“We are delighted to have secured this funding and are due to complete CE marking at the end of Q3. We will therefore introduce the GA-map™ IBS Dysbiosis Test at the upcoming UEGW conference in Berlin.” commented Stenersen. Chairman Mr. Rune Sørum, a partner in Norsk Innovasjonskapital AS added: “ Due to the track record of management and clear market need, there was strong interest in the funding and once we have achieved our initial objectives, we will be looking to commence a larger round in early 2014.”
About Genetic Analysis AS: Genetic Analysis AS (GA) is positioned to become a world leader within the field of molecular diagnostics of diseases related to gut imbalances. By utilizing the DNA-based GA-map™ array technology, profiles of a patient’s gut microbiota is quickly generated and can be related to various health conditions.
Richard Hayhurst
Richard Hayhurst Associates Ltd
3 Gloucester Road
Hampton
TW12 2UQ
UK
T: +44 (0) 7711821527
E: Richard@richardhayhurstassociates.com
W: www.richardhayhurstassociates.com
Help employers find you! Check out all the jobs and post your resume.
